Platelets最新文献

{"title":"Platelets induce VISTA expression and modulate the ovarian tumor microenvironment.","authors":"Hani Lee, Brianne Sager, Anil Sood, Vahid Afshar-Kharghan, Min Soon Cho","doi":"10.1080/09537104.2026.2644366","DOIUrl":"10.1080/09537104.2026.2644366","url":null,"abstract":"<p><p>Immune checkpoint regulators, such as the V-domain Ig suppressor of T cell activation (VISTA), play a critical role in shaping the tumor microenvironment (TME) and facilitating immune evasion. In ovarian cancer, VISTA exhibits more abundant and consistent expression than other immune checkpoints, including Programmed Death-Ligand 1 (PD-L1). This study examined the role of platelets in the regulation of VISTA in ovarian cancer using both in vitro and in vivo models. Our findings demonstrate that platelets upregulate VISTA expression in both myeloid and tumor cells, thereby promoting an immunosuppressive TME. Elevated VISTA levels were associated with higher platelet counts and poorer clinical outcomes. These results highlight that platelet-mediated VISTA upregulation is a potential therapeutic target for improving antitumor immune responses in ovarian cancer.</p>","PeriodicalId":20268,"journal":{"name":"Platelets","volume":"37 1","pages":"2644366"},"PeriodicalIF":3.1,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13231984/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147499595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pilot study on cannabis-induced alterations in platelet function: implications for transfusion medicine.","authors":"Geneviève Laflamme, Hind Hamzeh-Cognasse, Fabrice Cognasse, Lionel Loubaki","doi":"10.1080/09537104.2026.2644368","DOIUrl":"10.1080/09537104.2026.2644368","url":null,"abstract":"<p><p>Platelet transfusions are essential in the management of thrombocytopenia, bleeding disorders, and hematologic malignancies. With cannabis use rising worldwide, its impact on donor platelet quality and transfusion efficacy remains poorly understood. This study investigated the effects of cannabis joint extracts (CJE) on platelet activation, pro-coagulant phenotype, mitochondrial function, and cytokine/chemokine release, with implications for transfusion safety. Human platelets were exposed in vitro to increasing concentrations of two CJE with distinct cannabinoid profiles: Orchid (O-CJE, THC 10.4%, CBD 14.7%) and QCGold (G-CJE, THC 25.5%, CBD 0.04%). Platelet activation (CD62P, Annexin V), mitochondrial depolarization, ATP levels, aggregation responses, and cytokine secretion (CCL3, PF4) were assessed. RBC lysate experiments were performed to assess the role of hemolysis. The involvement of CB1 and CB2 receptors was tested using specific antagonists, and activation of p38 MAPK and NF-κB pathways was evaluated. Functional effects of platelet supernatants were examined on EA.hy926 endothelial cells. CJE exposure induced dose-dependent platelet activation, characterized by increased CD62P expression, Annexin V binding, mitochondrial depolarization, and ATP depletion, consistent with metabolic stress. Platelet aggregation in response to ADP, collagen, and arachidonic acid was impaired, suggesting a pre-activated or refractory phenotype. RBC lysate did not reproduce the observed effects, indicating hemolysis is unlikely to be the underlying mechanism. CBR1 and CBR2 antagonists did not attenuate platelet activation, while signaling analysis revealed activation of p38 MAPK and NF-κB pathways. Exploratory proteomics indicated modulation of proteins involved in angiogenesis, cytoskeletal organization, and stress responses. Elevated plasma levels of CCL3 and PF4 and endothelial activation (IL-6 secretion, CD54, CD62P, CD62E expression) further suggested a pro-inflammatory environment. Cannabis exposure can alter platelet phenotype and signaling under in vitro conditions, potentially affecting platelet function and interactions with the vascular endothelium. However, these findings require confirmation in vivo to determine their clinical relevance. Future studies should aim to establish exposure thresholds and clarify whether cannabis use has implications for transfusion safety, given potential risks of reduced efficacy or increased thrombotic complications in recipients.</p>","PeriodicalId":20268,"journal":{"name":"Platelets","volume":"37 1","pages":"2644368"},"PeriodicalIF":3.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147499491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GPVI deficiency reduces clot size and murine thrombosis in normoglycaemic but not hyperglycemic conditions.","authors":"Julia S Gauer, Cédric Duval, Helen R McPherson, Amanda D V MacCannell, Lee D Roberts, Khalid M Naseem, Ramzi A Ajjan, Robert A S Ariëns","doi":"10.1080/09537104.2026.2646681","DOIUrl":"10.1080/09537104.2026.2646681","url":null,"abstract":"<p><strong>Background: </strong>Glycoprotein (GP)VI is involved in platelet activation, procoagulant phenotype development and reactive oxygen species (ROS) production. Patients with diabetes have altered platelet reactivity and abnormal clot structure, contributing to elevated thrombosis risk. The role of GPVI in clot formation in hyperglycemia is under-investigated.</p><p><strong>Objectives: </strong>To compare the effect of GPVI-deficiency on ROS production and ex vivo and in vivo clot formation in normo- vs hyperglycemic mice.</p><p><strong>Methods: </strong>Wild-type (WT) and GPVI-deficient (GPVI^-/-) mice had access to hyperglycemic (30% sucrose) or normoglycaemic (standard) diet for 8-weeks. ROS and mitochondrial activity (CS) were measured in isolated platelets. Clot contraction was performed with whole blood. Thrombus formation in vivo was assessed by inferior vena cava (IVC) ligation.</p><p><strong>Results: </strong>Hyperglycemia increased ROS and CS activity in WT but not GPVI^-/- mice. Clot weight was decreased in GPVI^-/- vs WT mice in normoglycaemia, but these effects were lost in hyperglycemia. Clot weight after IVC ligation was reduced in GPVI^-/- vs WT mice in normoglycaemia, with the inverse observed in hyperglycemia.</p><p><strong>Conclusions: </strong>Our data suggest that clot formation is affected differentially by absence of GPVI in normo- vs hyperglycemia, supporting a role for GPVI in thrombosis under normoglycaemic conditions only.</p>","PeriodicalId":20268,"journal":{"name":"Platelets","volume":"37 1","pages":"2646681"},"PeriodicalIF":3.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147499468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Statement of Retraction.","authors":"","doi":"10.1080/09537104.2026.2722479","DOIUrl":"https://doi.org/10.1080/09537104.2026.2722479","url":null,"abstract":"","PeriodicalId":20268,"journal":{"name":"Platelets","volume":"37 1","pages":"2722479"},"PeriodicalIF":3.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148920712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Platelet-rich plasma concentrations regulate MSCs osteogenesis via MAPK/PI3K-AKT pathways to mitigate inflammatory bone loss.","authors":"Shaochuan Wang, Debin Guo, Shidan Li, Ruohui Tang, Hao Jiang, Xiaoming Li, Youbin Li, Jing Yang, Lei Li, Jun Fei","doi":"10.1080/09537104.2026.2642053","DOIUrl":"10.1080/09537104.2026.2642053","url":null,"abstract":"<p><p>Bone maintains a dynamic and stable state through the orchestration of osteoclasts and osteoblasts. Osteoblasts are derived mainly from mesenchymal stem cell (MSC) and are responsible for bone formation. The inhibition of osteoblast proliferation and differentiation is involved in many diseases, including osteoporosis, osteoarthritis, infected bone defects, and inflammatory aseptic loosening of implants. Given the currently limited treatment options, exploring new methods to promote bone formation is an important focus significant for orthopedists. Platelet-rich plasma (PRP), an autologous substance that is rich in various growth factors, is widely used in regenerative medicine. However, the effect of PRP on inflammatory bone destruction remains unclear. We investigated the effects of PRP on the viability of MSC, and the impact of different concentrations of PRP (1% and 3%, respectively) on cell death, proliferation, and differentiation. Furthermore, we tested the therapeutic effect of different concentrations of PRP (1% and 3%) on LPS-induced inflammatory bone destruction in vivo. PRP enhanced the cellular activity of MSC and promoted osteogenesis. A higher concentration of PRP (3%) primarily reduced the death and increased the proliferation of in LPS-treated MSC via the PI3K/AKT pathway, while a lower concentration of PRP (1%) promoted MSC differentiation into osteoblasts through the MAPK pathway. Consistent with in vitro experiments, we validated the protective effect of PRP against LPS-induced bone loss by increasing bone formation in vivo. These results suggest that different concentrations of PRP can ameliorate LPS-induced inflammatory bone loss through distinct mechanisms.</p>","PeriodicalId":20268,"journal":{"name":"Platelets","volume":"37 1","pages":"2642053"},"PeriodicalIF":3.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147623572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Functionality of platelets after in vitro testing of pulsatile total artificial hearts.","authors":"Per Sandgren, Shaikh Faisal Zaman, Ina Laura Perkins","doi":"10.1080/09537104.2026.2741743","DOIUrl":"https://doi.org/10.1080/09537104.2026.2741743","url":null,"abstract":"<p><p>Hemolysis is a metric of hemocompatibility in total artificial hearts (TAHs) but provides limited insight into platelet biology and thrombogenicity. We demonstrated reduced hemolysis with Realheart® TAH (RH) compared to FDA-approved SynCardia TAH (Sync). Here, we evaluated platelet function following exposure to both devices in a whole-blood in vitro system using a standardized ASTM F1830 protocol. Human blood (<i>n</i> = 5) was circulated for 360 min under controlled conditions (5 L/min, 100 mmHg, 37 °C) in RH, Sync, while matched static controls were maintained under identical temperature conditions. Platelets were assessed using metabolic (ATP, mitochondrial potential), phenotypic (surface markers, microparticles), and functional (agonist response, thromboelastometry) assays. Differences were observed between circulating and static conditions, including higher pH, increased lactate, and reduced platelet surface receptor expression, consistent with the non-physiological nature of static controls. Despite these changes, no evidence of increased platelet activation (CD62P), thrombogenicity (CD61⁺ microparticles), or mitochondrial damage (ATP, JC-1) was observed, and platelet function remained preserved by agonist stimulation and thromboelastometry. SynCardia increased mean platelet volume and reduced ATP levels, suggesting altered particle composition rather than intrinsic platelet dysfunction. These findings indicate preserved platelet integrity under clinically relevant TAH conditions and highlight that hemolysis and platelet responses represent distinct aspects of device hemocompatibility.</p>","PeriodicalId":20268,"journal":{"name":"Platelets","volume":"37 1","pages":"2741743"},"PeriodicalIF":3.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149195861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The use of light transmission aggregometry for monitoring platelet transfusion response in a small case cohort of Glanzmann thrombasthenia patients: a hypothesis-generating study.","authors":"Karlijn H G Rutten, Olga Tsiamita, Sean Platton, Mathieu Fiore, Rolf T Urbanus, Suthesh Sivapalaratnam, Roger E G Schutgens","doi":"10.1080/09537104.2026.2621761","DOIUrl":"10.1080/09537104.2026.2621761","url":null,"abstract":"<p><p>Light transmission aggregometry (LTA) is commonly used to diagnose platelet disorders and has a specific pattern in Glanzmann thrombasthenia (GT). As there is currently no adequate test to assess the efficacy of platelet transfusion, we explored whether LTA can be used to monitor the platelet response following platelet transfusion. We retrospectively evaluated LTA results after platelet transfusion in four patients with GT. After transfusion of two units of platelets, aggregation assessed by LTA remained reduced for all platelet agonists except ristocetin, despite a satisfactory clinical effect on hemostasis. One patient received seven units, after which a change in LTA results was observed. In this heterogeneous case cohort, the LTA response did not correlate with the clinical response after platelet transfusion in GT. To draw definitive conclusions, a study in a larger population that controls for influencing factors - such as the timing and dose of platelet transfusion and the use of a standardized LTA procedure - should be conducted.</p>","PeriodicalId":20268,"journal":{"name":"Platelets","volume":"37 1","pages":"2621761"},"PeriodicalIF":3.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146087053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neural network reveals platelet age from fluorescence microscopy images.","authors":"Johan A Slotman, Maurice Swinkels, Sophie Hordijk, Daan Te Rietmole, Bart Geverts, Petra E Bürgisser, Joyce Bestebroer, Ihor Smal, Thomas R L Klei, Adriaan B Houtsmuller, Frank W G Leebeek, Ruben Bierings, A J Gerard Jansen","doi":"10.1080/09537104.2026.2656268","DOIUrl":"10.1080/09537104.2026.2656268","url":null,"abstract":"<p><p>Platelets are small, anucleate cells with a primary physiological role in vascular damage repair (hemostasis) and initiation of thrombus formation in response to vascular injury. Platelets circulate approximately 7-10 days, slowly undergoing age-related changes in molecular composition, morphology, activation capacity, function, and surface receptor density. As older platelets are associated with poor clinical outcome, no <i>in vitro</i> tests are available to predict platelet age, or to determine the fitness of platelet transfusion products. In this study, we developed a convolutional neural network model that could determine platelets' chronological age from confocal microscopic images. The model was trained using platelets stored in platelet-rich plasma up to 8 hours and using routine platelet concentrates up to 10 days. The model predicted chronological age of stored platelets with >97% accuracy. To test our model <i>in vivo</i>, we analyzed a cohort of patients with acute myeloid leukemia, experiencing thrombocytopenia due to chemotherapy. Our model could reliably distinguish <i>in vivo</i> between samples with younger and older platelets during the course of treatment. This study demonstrates the ability to predict platelets' chronological age both <i>in vitro during storage</i> and <i>in vivo</i>, which may impact clinical transfusion medicine and the diagnosis and treatment of patients with platelet disorders.</p>","PeriodicalId":20268,"journal":{"name":"Platelets","volume":"37 1","pages":"2656268"},"PeriodicalIF":3.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147699604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immature platelet fraction as a prognostic marker in patients with pulmonary embolism.","authors":"Akiva Brin, Ranel Loutati, Ariella Tvito, Louay Taha, Mohammad Karmi, Dana Deeb, Mohammed Manassra, Noam Fink, Pierre Sabouret, Jamal S Rana, Mamas A Mamas, Ofir Rabi, Amro Moatz, Abed Qadan, Nir Levi, Michael Glikson, Elad Asher","doi":"10.1080/09537104.2026.2619763","DOIUrl":"10.1080/09537104.2026.2619763","url":null,"abstract":"<p><strong>Introduction: </strong>Immature platelet fraction (IPF), a population of young platelets with distinct histological and functional characteristics, is associated with adverse outcomes in several cardiovascular diseases. However, data on the role of IPF in acute pulmonary embolism (PE) is limited. The objective of this study was to evaluate the prognostic significance of IPF levels in patients with acute PE.</p><p><strong>Methods: </strong>All patients admitted to a tertiary care center's intensive cardiovascular care unit (ICCU) with confirmed diagnosis of acute PE from July 2019 to July 2024 were included. IPF measurement was carried out using an autoanalyzer (Sysmex XN-2000). The correlation between IPF level and outcome of all-cause mortality was assessed.</p><p><strong>Results: </strong>A total of 166 patients were included. Mean age of 65.0 years (±17.3), of whom 92 (55.4%) were male. The overall one-year mortality rate was 9.0% (15 patients), while the 30-day mortality rate was 4.8% (8 patients). Multivariate logistic regression analysis demonstrated that elevated IPF levels were independently associated with increased 30-day mortality (OR 1.36; 95% CI 1.06-1.80, <i>p</i> = .017) and one-year mortality (OR 1.23; 95% CI 1.02-1.5, <i>p</i> = .03).</p><p><strong>Conclusions: </strong>Elevated IPF levels are independently associated with increased 30-day and one-year mortality in patients with acute PE. These findings highlight the potential of IPF as a prognostic marker for short-term outcomes in this patient population.</p>","PeriodicalId":20268,"journal":{"name":"Platelets","volume":"37 1","pages":"2619763"},"PeriodicalIF":3.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148150968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sixty years of research into ancestry differences in platelet function.","authors":"Jillian Teichman, Andrew D Johnson","doi":"10.1080/09537104.2026.2649282","DOIUrl":"10.1080/09537104.2026.2649282","url":null,"abstract":"<p><p>Studies investigating the role of differential platelet function across various ancestry groups have been ongoing since at least the middle twentieth century. Consistently identified trends include differential frequency of CD36 deficiencies, variability in the efficacy of the antiplatelet functions of clopidogrel, increased PAR4 reactivity observed among African ancestry individuals, and reduced ristocetin-induced platelet aggregation also observed in African ancestry. Nonetheless, consensus is lacking in many areas. Replication in many of these studies is poor, utilized models may lack the necessary covariates to effectively capture environmental effects, and the represented cohorts disproportionately lean North American. Further comparative research of platelet phenotypes may yield important clinical insights and benefits; though to accomplish this a collaborative, international effort between institutes would be required. In this review, we discuss what is currently understood regarding differential platelet reactivity between ancestry groups, what areas are inadequately characterized, and the technical and organizational aspects which should be considered in future research.</p>","PeriodicalId":20268,"journal":{"name":"Platelets","volume":"37 1","pages":"2649282"},"PeriodicalIF":3.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13118511/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147628396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}